Viridian Therapeutics (VRDN) director-linked funds receive 32,341 options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Viridian Therapeutics director-associated funds received a new stock option grant linked to board service. Investment vehicles managed by Fairmount Funds Management LLC were granted an option covering 32,341 shares of Viridian common stock at an exercise price of $18.48 per share. The option vests in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, if Christopher W. Cain continues serving on Viridian’s Board of Directors. The option expires on July 1, 2036. Under Cain’s arrangement with Fairmount, any net cash or stock from the option must be turned over to the adviser for the benefit of the Fairmount funds, and Cain disclaims beneficial ownership of both the option and the underlying shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CAIN CHRISTOPHER W.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,341	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,341 shares (Indirect, See Footnote)

Footnotes (1)

The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Key Figures

Option grant size: 32,341 shares Exercise price: $18.48 per share Total options after grant: 32,341 options +2 more

5 metrics

Option grant size 32,341 shares Stock option covering Viridian common stock

Exercise price $18.48 per share Conversion or exercise price of the option

Total options after grant 32,341 options Total derivative shares following transaction

Option expiration July 1, 2036 Expiration date of stock option grant

Vesting date trigger July 1, 2027 Vests on earlier of this date or 2027 annual meeting

Key Terms

Stock Option (Right to Buy), beneficial ownership, annual meeting of stockholders, Board of Directors, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

beneficial ownership financial

"The Reporting Person therefore disclaims beneficial ownership of the option"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service"

Board of Directors financial

"continued service on the Board of Directors of the Issuer"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

investment vehicles financial

"the Reporting Person holds the option for one or more investment vehicles managed by the Adviser"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:17 PM Accepted by SEC EDGAR 07/02/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAIN CHRISTOPHER W.

(Last)

(First)

(Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$18.48	07/01/2026		A		32,341		⁽¹⁾	07/01/2036	Common Stock	32,341	$0.00	32,341	I	See Footnote⁽²⁾

Explanation of Responses:

1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

2. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

	/s/ Jennifer Tousignant, Attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did the latest Form 4 report for Viridian Therapeutics (VRDN)?

The Form 4 reports a grant of a stock option for 32,341 Viridian Therapeutics (VRDN) shares. The option is linked to director Christopher W. Cain’s board service but is held for investment vehicles managed by Fairmount Funds Management LLC, which benefit from any net proceeds.

How many Viridian Therapeutics (VRDN) shares are covered by the new option grant?

The option grant covers 32,341 shares of Viridian Therapeutics (VRDN) common stock. These shares are issuable upon exercise of the option, which was awarded in connection with Christopher W. Cain’s role on the Board and held for Fairmount-managed investment vehicles.

What is the exercise price and expiration date of the new VRDN option?

The option has an exercise price of $18.48 per Viridian Therapeutics (VRDN) share and expires on July 1, 2036. This gives the Fairmount-managed investment vehicles a long-dated right to buy shares if the vesting and service conditions are satisfied over time.

When does the new Viridian Therapeutics (VRDN) option vest?

The option vests in full on the earlier of July 1, 2027 or Viridian Therapeutics’ (VRDN) 2027 annual meeting of stockholders. Vesting is conditioned on Christopher W. Cain’s continued service on the company’s Board of Directors through that vesting event.

Who benefits economically from the new VRDN option grant linked to director Cain?

Economic benefits from the option go to investment vehicles managed by Fairmount Funds Management LLC, not directly to Christopher W. Cain. Cain must turn over any net cash or stock from the option to Fairmount, and he disclaims beneficial ownership of the option and underlying shares.

Is the VRDN option grant an open-market purchase or a compensation award?

The transaction is a compensation-related option award, not an open-market purchase of Viridian Therapeutics (VRDN) shares. It was reported with code A as a grant or award acquisition, tied to board service, with no cash paid per share at the time of grant.